Skip to main content
PFSA
NASDAQ Industrial Applications And Services

Profusa Files Prospectus Supplement for 179M Share Resale, Details New Highly Dilutive Equity Line Draw

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.451
Mkt Cap
$1.925M
52W Low
$0.403
52W High
$975.003
52W Position info
12% above low
Off High info
100% below high
Rel. Volume
Market data snapshot near publication time

PFSA is trading near its 52-week low of $0.403 (12% above the low).

Summary

Profusa filed a prospectus supplement for the resale of 179.3 million shares by selling stockholders, which could result in over 4000% dilution, and disclosed a new highly dilutive equity line draw with unfavorable pricing and a "true-up" mechanism.


Key Events · Financing and Capital Events · PFSA

  • Massive Potential Dilution

    A prospectus supplement registers 179.3 million shares for resale by selling stockholders, representing over 4000% potential dilution based on current shares outstanding.

  • No Direct Company Proceeds from Resale

    Profusa will not receive any proceeds from the sale of these 179.3 million shares by the selling stockholders.

  • New Highly Dilutive Equity Line Draw

    The company issued an "Advance Notice" to draw up to $300,000 from an equity line of credit, priced at 97% of the lowest 10-day VWAP, with a "true-up" mechanism that issues additional shares if the investor sells at a lower price.

  • Ongoing Financial Distress

    This dilutive financing occurs as Profusa faces a going concern warning, increased losses, and ongoing Nasdaq delisting threats, despite a recent exception to continue listing.


Analysis · PFSA · Industrial Applications And Services

This filing updates the registration for the resale of 179.3 million shares by selling stockholders, representing a potential dilution of over 4000% for existing shareholders, from which the company receives no direct proceeds. Critically, it also incorporates an 8-K detailing a new "Advance Notice" to draw funds from an equity line of credit. This draw is capped at $300,000 but comes with extremely dilutive terms, including pricing at 97% of the lowest volume-weighted average price and a "true-up" mechanism that issues additional shares if the investor sells at a lower price. This ongoing, highly dilutive financing activity is a desperate measure to maintain operations amidst severe financial distress, a going concern warning, and ongoing Nasdaq listing challenges.

At the time of this filing, PFSA was trading at $0.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.40 to $975.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PFSA - Latest Insights

PFSA
Jul 31, 2026, 5:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.860
Real-time Price: $0.9051 info
Change: +$0.0451 (+5%) info
Market Cap: $498.677K info
PFSA
Jul 31, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.870
Real-time Price: $0.9051 info
Change: +$0.0351 (+4%) info
Market Cap: $498.677K info
PFSA
Jul 27, 2026, 6:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $0.9051 info
Change: -$0.6649 (-42%) info
Market Cap: $498.677K info
PFSA
Jul 27, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $0.9051 info
Change: -$0.7349 (-45%) info
Market Cap: $498.677K info
PFSA
Jul 07, 2026, 8:52 AM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.088
Real-time Price: $0.9051 info
Change: Reverse Stock Split info
Market Cap: $498.677K info